Chang-Eui Hong¹, Su-Yun Lyu^2,*

BIOCELL, Vol.49, No.2, pp. 289-314, 2025, DOI:10.32604/biocell.2025.061334 - 28 February 2025

Abstract Objectives: Among cutaneous malignancies, melanoma stands out for its particularly aggressive nature, with therapeutic interventions becoming notably limited once the disease progresses. In this research, we investigate the tumor-suppressing capabilities of water-extracted Korean mistletoe (Viscum album var. coloratum) and its purified lectin component (V. album var. coloratum agglutinin, VCA) using two distinct mouse melanoma models: B16BL6 and B16F10 cell lines. Methods: The impact of water extract and VCA treatments on melanoma cells was assessed through multiple experimental approaches, examining cellular survival rates, programmed cell death pathways, multicaspase activity, and cell cycle distribution patterns. To elucidate the interconnections among… More >

Arshia Sandozi, Dhaval Jivanji, Yiwu Huang, Omar Azar, Ariel Schulman

Canadian Journal of Urology, Vol.29, No.5, pp. 11323-11325, 2022

Abstract Non-urothelial malignant ureteral obstruction (MUO) causes hydronephrosis, renal damage and infectious sequelae. The overall condition, symptoms, and plans for systemic therapy inform urologic intervention. In well-selected cases, there is a role for definitive reconstruction. We describe a robotic-assisted distal ureterectomy and reimplant for definitive repair of obstructive metastatic melanoma. More >

Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were More >